Drug-eluting stents (DES) were inserted in 180 patients (270 stents), mean age 63 years, and bare-metal stents (BMS) were inserted in 191 patients (301 stents), mean age 63 years, during percutaneous coronary intervention. Baseline characteristics were similar for patients treated with DES or BMS. The average stent length was longer for DES (16.83 mm) versus BMS (15.45 mm) (P = 0.0026). The average stent diameter was shorter for DES (2.89 mm) versus BMS (3.00 mm) (P = 0.00027). In-hospital stent thrombosis occurred in one of 270 DES (0.4%) versus three3 of 301 BMS (1.0%) (P = not significant).

e13053 Background: Bortezomib, a proteosome inhibitor is an effective drug in treatment of multiple myeloma (MM). As single agent and in combination with other drugs it not only has antitumor effect but has also increased survival. There are many side effects associated with its use, including peripheral neuropathy. We report incidence of chalazion in myeloma patients treated with bortezomib. Methods: On clinical Chart review, there were 34 patients with stage 3 MM treated with bortezomib in 2010 and 2011 in a community oncology practice. There were 18 females, and 16 males. Their age ranging from 52-76 years with a median of 68years. There were 17 African American (AA) and 17 non African American (NAA) patients. 14 patients received single agent bortezomib, 10 received it in combination with dexamethasone, and other 10 in combination with lenalidomide, cyclophosphamide and steroids. All patients received bisphosphantes. Results: Four patients developed chalazion 11 to 22 months into treatment with bortezomib. Chalazion was relatively resistant to conventional therapy offered by the ophthalmologists, and persisted during therapy with bortezomib. 1 patient needed surgical intervention. 3 out of 4 patients were AA. There was no incidence of chalazion noted in solid tumor patients treated with chemotherapy that did not include bortezomib in the same time period. Conclusions: We believe, prolonged use of bortezomib is associated with 12-15% incidence of chalazion, which is relatively resistant to conventional therapy, and persist during use of bortezomib.

e20722 Background: Outpatient chemotherapy/biotherapy in oncologist's offices are being utilized in greater numbers, increasing the risks of acute allergic reactions. Methods: The clinical charts of patients receieving prolonged infusion chemotherapy/biotherapy treatments (1–3 hours of infusion) in a community oncologist's office setting were reviewed to determine the rate(risk), management and outcome of severe acute allergic reactions. Results: From January 2007 to December 2008, there were 1453 patient infusions conducted. 653 infusions in 2007 and 800 in 2008. All patients were premedicated with antiemetics, H2 blockers if indicated and dexamethasone. In addition starting 2008 patients also recieved diphenhydramine 25mg. There were total of 15 aute allergic reactions. 10 patients with respiratory symptoms(cough/dysponea/wheezing), 3 patients developed anaphylactic reactions, and 2 patients developed rash. Chemotherapy infusions were promptly discontinued and appropriate resusitative measures instituted. The drugs to which reactions occured included 6 to docetaxel, 3 paclitaxel, 3 carboplatin. and 3 oxaliplatin. All patients responded to resusitative measures which included IV fluids, oxygen, subcutaneous epinephrine, IV dexamethasone, and IV diphenhydramine. None required assisted ventilation or cardio version. All patients were discharged home after 1 to 3 hours of observation. Conclusions: Acute allergic reactions to anticancer therapy must be anticipated in all cases. Appropraite preventive protocols and prompt response will minimize the morbidity and eliminate mortality. No significant financial relationships to disclose.

No abstract

10614 Background: Aromatse Inhibitors are a class of drugs that inhibit tumor growth in hormone receptor positive breast cancers in postmenopausal women. They exert their action by inhibiting the enzyme aromatse involved in the last step in conversion of Androgens to estrogens. They are currently used extensively in both advanced and adjuvant treatments. Methods: Clinical Charts of postmenopausal women, with estrogen receptor positive breast cancer, receiving the non-steroidal aromatse inhibitor, Anastrazole 1 mg daily at a community oncology practice were evaluated for androgenic effect of the drug. Review included presence of clinical Hirsutism and serum testosterone levels. Results: There were 33 women, receiving Anastrazole, 29 for adjuvant therapy, and 4 for metastatic disease. Age 51–77years (median: 63 years), Duration of Anastrazole therapy 6 months to 42 months (median: 18 months), There was no Clinical evidence of hirsutism noted. Serum testosterone levels varied from 9 ng/ml to 58 ng/ml. (Normal range: 14–76 ng/ml) in 32 women. 1 woman had a serum testosterone level of 86 ng/ml with no clinical hirsutism. The most common side effect of Anastrazole was arthralgias, seen in three women. Conclusions: Anastrozole 1 mg daily does not appear to cause any clinical androgenic effect, or elevation of serum testosterone levels. No significant financial relationships to disclose.